Nephrotoxicity is a major problem in the preclinical and clinical setting that results in the failure of candidate compounds throughout the drug-development cycle. An article in this month’s GEN outlines the development of a new generation of biomarkers for drug-induced toxicity that provides greater sensitivity and earlier detection than previous methods.